Tango Therapeutics (TNGX) Expected to Announce Quarterly Earnings on Monday

Key Points

• Q1 2026 results due before market open on Monday, May 11; analysts forecast a loss of about ($0.32) EPS and revenue of roughly $0.578 million, with an earnings call scheduled for Friday, May 15 at 9:00 AM ET.
• TNGX shares jumped about 6.5% to $22.34 in mid-day trading (market cap ~$3.22B), trading well below its 52-week high of $28.41 but far above its 52-week low of $1.03.
• Wall Street shows a consensus "Moderate Buy" stance with an average target of $22.44 (11 buys, 1 hold, 1 sell), while insiders have sold ~211,344 shares (~$3.5M) over the past three months and now own 7.5% of the stock.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.32) per share and revenue of $0.5780 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:00 AM ET.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Tango Therapeutics Stock Up 6.5%

Shares of TNGX stock traded up $1.36 during mid-day trading on Monday, hitting $22.34. 342,858 shares of the company's stock were exchanged, compared to its average volume of 3,272,201. Tango Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $28.41. The stock has a 50-day simple moving average of $19.50 and a two-hundred day simple moving average of $13.34. The stock has a market cap of $3.22 billion, a price-to-earnings ratio of -25.49 and a beta of 1.22.

Wall Street Analyst Weigh In

TNGX has been the topic of several analyst reports. Wall Street Zen cut Tango Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 21st. HC Wainwright raised their price objective on Tango Therapeutics from $13.00 to $27.00 and gave the stock a "buy" rating in a report on Friday, March 6th. Piper Sandler raised their price objective on Tango Therapeutics from $11.00 to $14.00 and gave the stock an "overweight" rating in a report on Friday, January 16th. Guggenheim increased their target price on Tango Therapeutics from $18.00 to $20.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Finally, Canaccord Genuity Group began coverage on Tango Therapeutics in a research report on Thursday, April 2nd. They issued a "buy" rating and a $30.00 target price on the stock. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tango Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $22.44.

Insider Buying and Selling at Tango Therapeutics

In other news, Director Barbara Weber sold 30,519 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $374,162.94. Following the sale, the director directly owned 1,629,254 shares of the company's stock, valued at approximately $19,974,654.04. The trade was a 1.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Daniella Beckman sold 10,317 shares of Tango Therapeutics stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the sale, the chief financial officer directly owned 184,297 shares in the company, valued at approximately $2,259,481.22. The trade was a 5.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 211,344 shares of company stock valued at $3,499,842 over the last three months. 7.50% of the stock is owned by company insiders.

Institutional Trading of Tango Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TNGX. Invesco Ltd. increased its position in shares of Tango Therapeutics by 138.8% during the first quarter. Invesco Ltd. now owns 70,517 shares of the company's stock worth $97,000 after acquiring an additional 40,983 shares during the last quarter. AQR Capital Management LLC acquired a new position in Tango Therapeutics in the first quarter worth about $195,000. Dynamic Technology Lab Private Ltd grew its stake in Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock worth $35,000 after purchasing an additional 15,037 shares in the last quarter. Woodline Partners LP grew its stake in Tango Therapeutics by 28.3% in the first quarter. Woodline Partners LP now owns 506,188 shares of the company's stock worth $693,000 after purchasing an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in Tango Therapeutics by 270.6% in the first quarter. Jane Street Group LLC now owns 352,897 shares of the company's stock worth $483,000 after purchasing an additional 257,668 shares in the last quarter. 78.99% of the stock is owned by hedge funds and other institutional investors.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.